Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relamorelin Phase 2b in Diabetic Gastroparesis
NCT02357420Phase 2Completed
- Sponsor
- Allergan
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Peptides, Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of relamorelin in diabetic gastroparesis (4 arms), sponsored by Allergan. Primary endpoint: Change From Baseline to Week 12 in Weekly Vomiting Episodes. Started Jan 2015; status: completed.
02
Drugs
relamorelin
03
Conditions
diabetic gastroparesis
Beyond the preview
Go deeper on NCT02357420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357420.